Indeed, that's the "delivery platform," or suspension, encapsulating the "the viral protein" (or synthetic RNA). The former is known to interested parties, the latter is not well reported.

After injection, the mRNA from the vaccine is released into the cytoplasm of the cells. Once the viral protein is made [HOW?] and on the surface of the cell, mRNA is broken down [metabolized?] and the body permanently gets rid of it[see? this is why ppl be searching for "black box warnings" and biochemical summaries exactly describing eg. waste product, bc EUA holders' reporting is faint], therefore making it impossible to change our DNA.

I must stress, I am not and have never suggested mRNA material alters cellular DNA. Rather like creation of "cancer cells", cellular DNA prescribes/transcribes mRNA transformation of normal surface structure ("binding domain") of human cells, mainly epithelial, which occur in form or another as tissue throughout the human body, into an unpredictable "pathway" of lymphatic responses to any and all antigens, including SARS-CoV-2. The mRNA mechanisms of action (MOA) said to "protect" cells is not well-understood.

Comirnaty

Comirnaty contains nucleoside modified mRNA (modRNA) encapsulated in lipid nanoparticles that deliver the modRNA into host cells. The lipid nanoparticle formulation facilitates the delivery of the RNA into human cells.12 Once inside these cells, the modRNA is translated by host machinery to produce a modified SARS-CoV-2 spike (S) protein antigen, which is subsequently recognized by the host immune system. Comirnaty has been shown to elicit both neutralizing antibody and cellular immune responses to the S protein, which helps protect against subsequent SARS-CoV-2 infection

AbsorptionNot Available

Volume of distribution Not Available

Protein binding Not Available

Metabolism Not Available
Route of elimination Not Available

Half-life Not Available

Clearance Not Available

etc

a nlm.nih.gov production

Comirnaty

CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
The nucleoside-modified mRNA in COMIRNATY is formulated in [INACTIVE INGREDIENTS], which enable delivery of the mRNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which protects against COVID-19.

neither DailyMed nor DrugBank describe the one ACTIVE INGREDIENT, Tozinameran

which being "recobinant" RNA, should be identifiable by its genomic sequence.